射频消融联合经门静脉导管药盒系统治疗肝癌

Radiofrequency Thermal Ablation Combined with Portal Vein Port-catheter Kit System in the Treatment of Hepatic Carcinoma

【目的】探讨射频消融联合经门静脉导管药盒系统治疗肝癌的方法和疗效。【方法】手术不能切除且不宜行介入栓塞治疗的原发性和转移性肝癌患者 33例 ,先行射频消融治疗后 ,再经门静脉导管药盒系统行化学治疗。【结果】射频消融治疗和经皮肝穿刺门静脉导管系统植入术均获得成功 ,未出现严重并发症。联合治疗后肝脏病灶部分缓解 (PR) 12 .1% ,稳定 (SD) 30 .3%。【结论】射频消融联合经门静脉导管药盒系统生物化疗能明显改善晚期原发性肝癌患者的症状和生活质量 ,并取得较好局部疗效。

ObjectiveTo evaluate the method and clinical efficacy of radiofrequency thermal ablation(RFTA) combined with percutaneous transhepatic portal vein port-catheter kit system(PVPCS) in the treatment of hepatic carcinoma (HC).In 33 patients with advanced primary or metastatic HC ,surgical resection could not be performed and embolus intervention therapy was also not suitable. They were selected to be treated with RFTA under ultrasound, then the chemotherapy was scheduled through percutaneous transhepatic PVPCS.Both of RFTA and percutaneous transhepatic PVPCS were successful, without severe complication. The partial remission rate of hepatic lesions after combined therapy was 12.1%, while the rate of stabilized cases was 30.3%.[Conclusion]RFTA combined with chemotherapy through PVPCS can markedly relieve the symptoms and inprove the life quality of patients with advanced primary HC, thus better local therapeutic efficacy is obtained.